Pharmacy Personnel Assessments of Workflow Associated with Medication Therapy Management Conducted During Transitions-of-Care by Tao, Allan W.
University of Kentucky 
UKnowledge 
MPA/MPP Capstone Projects Martin School of Public Policy and Administration 
2018 
Pharmacy Personnel Assessments of Workflow Associated with 
Medication Therapy Management Conducted During Transitions-
of-Care 
Allan W. Tao 
University of Kentucky, awta223@uky.edu 
Follow this and additional works at: https://uknowledge.uky.edu/mpampp_etds 
 Part of the Pharmacy and Pharmaceutical Sciences Commons, and the Rehabilitation and Therapy 
Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Tao, Allan W., "Pharmacy Personnel Assessments of Workflow Associated with Medication Therapy 
Management Conducted During Transitions-of-Care" (2018). MPA/MPP Capstone Projects. 307. 
https://uknowledge.uky.edu/mpampp_etds/307 
This Graduate Capstone Project is brought to you for free and open access by the Martin School of Public Policy 
and Administration at UKnowledge. It has been accepted for inclusion in MPA/MPP Capstone Projects by an 
authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu. 
Tao 1 
  
 
   
  
  
  
Pharmacy Personnel Assessments of Workflow 
Associated with Medication Therapy Management 
Conducted During Transitions-of-Care  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
Allan W. Tao 
  
PharmD / MPA Candidate 2018  
  
University of Kentucky College of Pharmacy  
  
Martin School of Public Policy and Administration  
  
Spring 2018 Graduate Capstone  
  
  
     
  
Tao 2 
  
 
 
 
 
 
       Table of Contents 
  
Executive Summary .................................................................................................................. 3 
Background .............................................................................................................................. 4 
Problem Statement ................................................................................................................. 16 
Literature Review .................................................................................................................... 17 
Research Design .................................................................................................................... 19 
Results .................................................................................................................................... 23 
Discussion .............................................................................................................................. 28 
Conclusion .............................................................................................................................. 33 
Limitations .............................................................................................................................. 34 
Citations .................................................................................................................................. 35 
Appendix A: Survey ................................................................................................................ 37 
 
  
 
Tao 3 
  
 
Executive Summary  
  
Pharmacists are known for their expertise with medications and are the first 
medical professionals that many patients seek for their day-to-day concerns. The 
importance of understanding one’s medication and having appropriate oversight over the 
regimen cannot be understated. There is exists a method, known as Medication Therapy 
Management (MTM), with which pharmacists can ensure medication therapy safety and 
appropriateness via patient interview and receive reimbursement from third-party payers 
like insurance companies. However despite this, MTM is not a widely known service 
amongst eligible patients. 
This study focuses on the process of MTM in UK Healthcare outpatient clinics and 
works to determine the main barriers between the idea and implementation of MTMs. 
Survey data was collected from ambulatory care pharmacists regarding their opinions on 
MTMs in order to determine whether or not a workflow solution would address the current 
lack. The responses regarding the barriers collected suggest that there is opportunity for 
a process-driven solution in the realm of outpatient MTM and that a newly developed 
workflow could facilitate the introduction of MTM into different realms of patient care such 
as during the transitions-of-care period. Additionally, utilizing time estimates, a time 
saving process has the potential to reduce the institutional cost of conducting MTMs by 
nearly half – possibly allowing the service to become profitable from a solely financial 
standpoint. The study highlights both the desire for pharmacists to provide a service they 
find value in as well as some of the external factors regarding MTM that will need to be 
addressed on a whole.  
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Background  
  
The field of healthcare is ever growing, as is the push towards proactive patient care. 
Patients are now expected by their healthcare team of medical professionals to invest 
and participate in their own care rather than observing from the sidelines (Barry et al., 
2012). The previous doctor-patient relationship, where decision making rested solely in 
the hands of the doctor, has changed due to patient dissatisfaction related to decisions 
they disagree with or were not informed about; both of which subsequently led to failure 
of therapy (Vermeire et al., 2001). As the number of sources for information grows in both 
print media and on the internet, the question of whether or not this movement towards 
patient engagement will be beneficial comes down to health literacy. Health literacy refers 
to “a set of skills that people need to function effectively in the health care environment” 
(Berkman et al., 2011). These skills include but are not limited to the following: the ability 
to read and understand text, to locate and interpret information in a document, to use 
quantitative information for tasks, to follow directions on medication regimen and to speak 
and listen effectively (Berkman et al., 2011). According to various studies, low health 
literacy has not only been associated with increased hospitalizations, but also with lower 
ability to take medication appropriately and lower probability of engaging in preventative 
services (Berkman et al., 2011). 
 
To combat low health literacy and promote movement towards patient-oriented 
care, pharmacists are being asked to take increasingly larger roles in patient-centered 
care by leveraging any extra time the patient may have, to further educate them on their 
medications. Pharmacists are traditionally seen as experts of medication but are 
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perceived differently based on where patients encounter them. In the outpatient setting, 
meaning locations such as retail stores or long-term care clinics, pharmacists are often 
seen solely as dispensers of medication, despite being the first contact for patients’ health 
questions and the last check of clinical appropriateness for medications. Inpatient (or 
hospital) pharmacists may be relatively unknown to the public but have an equal part in 
a patient’s care as outpatient pharmacists – some will perform a similar job duty of 
checking and dispensing medications while others will work with doctors to develop plans 
of care for patients. Although the push for pharmacy involvement is new, the process is 
not – traditionally there are three prime questions used to address new prescriptions a 
patient has received, namely; “what did your doctor tell you the medication is for”, “how 
did your doctor tell you to take the medication”, and “what did your doctor tell you to 
expect” (Wertheimer, 1996). These three questions would eventually grow into the 
concept now known as Medication Therapy Management (MTM).  
 
Figure 1: Outpatient vs. Inpatient pharmacist-patient interaction 
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Medication Therapy Management 
The history of MTM dates back to the 1990’s where it was referred to as “pharmaceutical 
care”. A consensus definition for MTM was established in 2005 by the American 
Pharmacists Association (APhA), a national pharmacist organization, and in 2008 billing 
codes became available for providers to receive monetary compensation or 
“reimbursement” for these services (Viswanathan et al., 2015). Providers are distinctly 
defined medical professionals who are given the ability to bill governmental programs 
such as Medicare and Medicaid – the definitions of a “provider” varies from state to state. 
Medicare, the government provided health insurance for the elderly and disabled, 
established laws in order to further the provision of MTM to the patients it covers. Within 
Medicare there are different “parts” offered by the government: Part D involves coverage 
for prescription medication and pharmacy benefits in the outpatient setting (Centers for 
Medicare & Medicaid Services, 2017). 
 
Under the Centers for Medicare and Medicaid Services (CMS), the Administrative 
Committee of the Federal Register established drug utilization management, quality 
assurance, and medication therapy management programs via 42 CFR 423.153. From 
this, the current definition of MTM has been established {Table 1}. Insurance companies 
who contract with CMS to provide specifically defined MTM programs in exchange for 
reimbursement are termed “Part D sponsors”. These MTM programs are designed for 
certain Medicare Part D patients who have various complex medical conditions or are on 
a significant amount of medications {Table 1}. MTM involves a large variety of services 
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including immunizations, anticoagulation management, and medication therapy reviews 
(Viswanathan et al., 2014).   
Table 1: Requirements of an MTM program 
Per §423.153(d), a Part D sponsor must have established an MTM program that… 
 Is designed to ensure that covered Part D drugs prescribed to targeted 
beneficiaries are appropriately used to optimize therapeutic outcomes through 
improved medication use 
 Is designed to reduce the risk of adverse events, including adverse drug 
interactions, for targeted beneficiaries 
 May be furnished by a pharmacist or other qualified provider 
 May distinguish between services in ambulatory and institutional settings 
 Must be developed in cooperation with licensed and practicing pharmacists 
and physicians 
Targeted Beneficiaries are enrollees in sponsor’s Part D plan who meet all of the 
following 
 Have multiple chronic diseases, with three chronic diseases being the 
maximum number a Part D plan sponsor may require for targeted enrollment 
 Are taking multiple Part D drugs, with eight Part D drugs being the maximum 
number of drugs a Part D plan sponsor may require for targeted enrollment 
 Are likely to incur (for 2012 and subsequent year) an amount greater than or 
equal to $3000 in annual Part D drug costs, increased by the annual 
percentage specified in §423.104(d)(5)(iv) – [annual percentage increase for 
each year is equal to the annual percentage increase in the consumer price 
index for all urban consumers for the 12-month period ending in July of the 
previous year] 
Legal Information Institute. (2015, February 12). 42 CFR 423.104. From 
https://www.law.cornell.edu/cfr/text/42/423.104#d_5_iv (Last accessed on 12/13/17). 
 
Comprehensive Medication Reviews 
One of the key services within the larger category of MTM are Comprehensive Medication 
Reviews (CMRs). A CMR is an involved process where the patient’s medication history, 
current regimen, medication problems, and needed interventions are compiled into one 
take-home packet. CMS has an expected definition for this but does not outline the 
requirements to the same degree as it has with MTM. The take-home packet is officially 
termed the “MTM Program Standardized Format” or Form CMS-10396. This packet is the 
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physical set of documents that CMS requires be delivered to the patient in order for either 
the pharmacist or the Part D sponsor to collect reimbursement (Centers for Medicare & 
Medicaid Services 2012). A typical CMR begins with reaching out to the patient with the 
offer and a brief description of the process. If the offer is accepted, the pharmacist will 
conduct an interview with the patient to confirm the patient’s current medication history, 
screen this developed list for any interactions or safety concerns, and address any 
concerns that the patient may have regarding their medication. Although the interview 
may occur over the phone, it is preferable to have it take place in-person given potential 
miscommunication through lack of non-verbal cues. The process on a whole can take 
from thirty to ninety minutes dependent on the complexity of a patient’s case. If the offer 
is declined or the patient is unable to be reached with at least three attempts, then the 
pharmacist will note this for documentation as well. 
 
This service is increasingly being recognized as beneficial for preventing adverse 
drug events, improving patient understanding, and aiding appropriate medication usage 
(Viswanathan et al., 2014). Additionally, Part D sponsors have a strong financial incentive 
to encourage pharmacists to complete these CMRs. Part D sponsors are evaluated by 
CMS on the percentage of eligible patients whom have received the service. These 
ratings take the form of “star ratings” which are used by Medicare patients when deciding 
upon a Part D health insurance plan and company. Despite this, the service has not 
become a frequent part of pharmacists’ workload due to the onerous steps involved and 
inadequate reimbursement obtained. 
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Figure 2: Insurance and Pharmacy Network 
 
 
Whereas Part D sponsors are being evaluated by CMS on CMR completion 
percentages, retail pharmacies are only loosely tied into the star-rating system. Retail 
pharmacies are involved in a Part D sponsor’s network as the sponsor will designate 
specific pharmacies the patient must pick-up their medications from in order to have them 
covered by the sponsor’s Medicare plan. Thus if a Part D sponsor’s star rating is 
negatively affected, it follows that fewer patients would want to select the sponsor’s 
particular Medicare plan and the designated pharmacies would receive fewer patients. 
As such, Part D sponsors will often use CMR completion percentage as a negotiating tool 
with their contracted retail pharmacies. However, for a retail pharmacy, potential losses 
in revenue via contract along with the additional revenue provided by the Part D sponsors 
for conducting CMRs have not proved to be crucial for daily operations. 
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Outpatient CMRs 
Currently, CMRs are mainly conducted in the outpatient setting – retail pharmacies 
encourage their pharmacists to offer CMRs to patient over the phone and during all points 
of patient-pharmacist contact. Web-based administration companies such as 
OutcomesMTM or Mirixia contract with multiple Part D sponsors to provide an efficient 
way to connect pharmacy service to a source of revenue. These companies will compile 
a broad summary of what the patient is likely taking – in normal course of business, 
pharmacies request reimbursement from Part D sponsors for the drugs dispensed that 
are covered by the patient’s insurance plan. From the complied record of dispenses, an 
estimation of the patient’s medication history is derived. This list is not necessarily 
complete as the patient may be taking over-the-counter or prescription medications that 
were not billed to a Part D sponsor. With this preliminary list, the web-based 
administration companies provide a web form for pharmacies to validate with patient 
information after the patient interview portion has been completed. The pharmacist notes 
any interventions made, as well as concerns brought up by the patient, in the form. The 
web-based administrative companies then take all information submitted by the 
pharmacist and reshape it into the MTM Program Standardized Format as required by 
CMS. At this point, the pharmacist is responsible for delivering this constructed take-home 
packet to the patient. 
 
Each of the Part D sponsors will review the web forms submitted by the web-based 
administration companies and pass on a portion of the larger reimbursement to them. 
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These companies in turn pass a portion of their reimbursement onto pharmacies as fee 
for the legwork. The portion that pharmacies receive ends up being around $50-100 
(OutcomesMTM, 2017). Considering that OutcomesMTM reported a Return-on-
Investment per pharmacist-identified cost-savings intervention of $656.39 in its 2016 
MTM Trends Report, the $50-100 given per patient can be argued as inadequate for the 
work’s value (OutcomesMTM, 2016). 
 
Outpatient retail pharmacists have the most patient interaction opportunities out of 
all facets of the profession. However, as stated before, the provision of CMRs is not a 
heavily marketed service by retail pharmacies. This is because the reimbursement fails 
to make up for the lack of available time and interest in CMRs for both the pharmacist 
and the patients. Additionally, there is an ongoing time struggle between patients who 
demand that their medications be affordable and filled quickly versus pharmacists who 
are obligated to ensure clinical appropriateness and safety. Patients will often not see the 
benefit in a service such as CMR given that benefits are typically not immediate, whereas 
the hassle of an in-depth interview is readily apparent – the scheduling of time, the 
previously described process of compiling a medication list, the attention that a medically 
complicated patient requires, etc. Pharmacists may instead focus on the medication 
checking and dispensing side of the job in order to appease their customers – even those 
who recognize the patient benefits in CMRs may be hesitant to devote time to it given 
that they are not correctly incentivized. 
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Inpatient CMRs 
CMS utilizes a different payment program with Medicare for the inpatient setting. Instead 
of Part D, Medicare Part B covers services provided by the hospital, durable medical 
equipment, as well as some preventative services. Programs similar to CMRs have been 
suggested as valuable initiatives in the inpatient setting. Although CMS allows Pharmacist 
Clinicians to receive Medicare Part D reimbursement, CMS does not currently recognize 
Pharmacist Clinicians as healthcare providers eligible for Medicare Part B 
reimbursement, thus hospitals often must work with third-party payers to ensure that 
reimbursement for MTM services is possible (UNM Medical Group, 2014). 
 
Inpatient pharmacists have a different angle with relation to patient care as their 
degree of patient interaction is limited to the patient’s stay in the hospital. Pharmacists 
have similar time pressures as their retail counterparts but are not confronted as often by 
the patient. The hospital would be an ideal setting for CMRs given that the patient is more 
readily available for consultation, their medication history is up-to-date pursuant to other 
pharmacy-related services, and consultation with other providers regarding complex 
interventions is facilitated by proximity. The patient is unable to leave as placed discharge 
orders do not mean that the patient is allowed to physically leave the hospital; a 
pharmacist conducting a CMR at this time would have a captive audience here, bypassing 
the time issue that arose in the outpatient scenario. The main issue with CMRs in the 
inpatient setting is the complete lack of reimbursement from Medicare for pharmacist 
work. As mentioned before, pharmacists are not eligible for reimbursement from Medicare 
Part B due to lack of provider status and Part D does not apply to the inpatient setting. 
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Transitions of Care 
The time between a patient’s hospital stay after discharge (hospital orders that declare a 
patient fit for leaving the hospital) and returning to home is defined as the “transitions of 
care” period. Transitions of care represents the transference of responsibility from the 
inpatient providers to the patient and their primary care provider. This time frame proves 
to be fraught with errors given that patients will have “prescription medicines commonly 
altered at this transition point” with “[s]elf-care responsibilities [that] also increase in 
number and importance” (Kripalani et al., 2007). According to Kripalani et al., 49% “of 
hospitalized patients experience at least 1 medical error in medication continuity, 
diagnostic workup, or test follow-up”. When looking specifically at adverse drug events, 
they are reported to occur in 19-23% of patients. Due to the barriers present in the 
outpatient realm and difficulty faced in the inpatient setting, this alternative time period 
has been suggested for conducting these MTM services. 
 
This short time period technically falls under the outpatient realm. The responsibility of 
the patient’s care has been transferred from the hospital staff to the patient’s primary care 
provider despite the fact that the patient physically resides in the hospital. Patients often 
remain in their room and are not allowed to leave until final preparations by various 
hospital staff have been made as discharge orders put in by a doctor only signify the need 
for staff to arrange follow-up appointments, transportation, financial matters, printing and 
preparation of all papers, and a final discussion with the patient to ensure understanding 
(UpToDate, 2017). Although the proposal of CMR in this time frame is relatively 
unexplored, the idea of pharmacy providing a service during this time frame is not. 
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Hospital-based retail pharmacies, those which serve an outpatient population but are 
either affiliated or owned by the hospital center, have developed programs to provide 
recently discharged patients with their first dose of new medications (UK HealthCare 
Pharmacy Services, 2017). The provision of a CMR during this same period would thus 
be conducting an outpatient service. This combines the benefits of both the outpatient 
and inpatient settings to negate the detriments of each – the patient is available for this 
service given their physical location in the hospital and pharmacists are able to receive 
reimbursement according to Part D MTM guidelines.  
 
The remaining issues with providing CMR services during the transitions of care 
timeframe includes the pharmacist’s availability to conduct them and the financial benefit 
of the service itself. From a strictly financial standpoint, each successfully conducted CMR 
will net a pharmacy between $50 and $100 (OutcomesMTM, 2017). Adding the factors of 
time required to aggregate a patient’s medication history, interview, develop a relevant 
action plan, and submit the documentation, the premium of a pharmacist’s time may 
outweigh the current dollar amount provided. This calculation is slightly blunted by the 
fact that hospital-based pharmacies are often interested in long-term patient health given 
that it may reduce hospital costs in other areas – shown by values such as Return-on-
Investment (OutcomesMTM, 2016). One example of this cost is patient readmission, 
where CMS will reduce Medicare payments for hospitals with excess readmissions 
(Centers for Medicare & Medicaid Services, 2015). The overall goal would be to distribute 
the work needed by dividing a transitions-of-care CMR into portions that can be 
conducted via a pharmacy technician against portions that require a pharmacist’s 
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expertise. This would allow for pharmacists to efficiently allocate their time while ensuring 
that the venture remains profitable for the hospital.  
 
At the University of Kentucky Chandler Medical Center, the transitions-of-care CMR is 
currently being explored as a viable realm for CMRs. In doing so, the University of 
Kentucky aims to improve patient outcomes while increasing total reimbursement 
received ensuring the long-term viability of providing CMRs. Given the undeveloped 
nature of CMR application in this timeframe, there have not yet been proven methods for 
providing these services. The nature of this research stems from the need to develop one 
such possible method in order to address the remaining issue of financial sustainability 
and potential additional health benefits that may result.  The first step of this research 
involves polling pharmacists in the retail setting about the significance of CMRs in order 
to identify potential barriers that will counteract this process.
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Problem Statement  
  
 Both the outpatient and the transitions-of-care realm will be considered. Although 
the patient health benefits and the financial benefits for Part D sponsors are widely known, 
CMRs have not become widely used in the outpatient area. This research endeavors to 
pin down the most influential reasons as to this non-use. These barriers fall into a few 
broad categories. First, there is the question of value, both on the side of the pharmacist 
and the side of the patient. The perceived value of the service in both parties in terms of 
health or financial benefit could largely affect the amount of CMRs provided. Logically, 
patients who understand the benefits would be more likely to request the service and 
pharmacists would be more likely to seek out patients who need them. Secondly, the time 
needed to conduct a CMR is a potential significant barrier. A service that requires 
preparatory work in addition to an interview consumes time that a retail pharmacist could 
use otherwise with checking prescriptions, patient counseling, or working out insurance 
issues, not to mention the time burden on the patient themselves. Communication and 
patient interaction is the third proposed barrier which comes into play in contacting 
patients, informing them of the service, and within the interview itself. This is not as readily 
apparent as value or time however the importance of patient engagement and 
participation in the process merits lack of these as potential problems. Finally from the 
perspective of the pharmacist, insufficient resources or a lack of understanding of the 
process can prevent effective utilization of CMRs. All of these problems carry over from 
the current retail setting to the transitions-of-care setting and thus are important to 
address before implementation of any new process. 
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Literature Review   
  
The literature around this inquiry of developing a workflow for Medication Therapy 
Management programs in the outpatient, transitions-of-care setting has not been 
previously explored. There have been previous studies that look into the benefit of MTM 
(which have subsequently been used to justify the requirement placed by the Centers for 
Medicare and Medicaid), however these are limited to the efficacy and outcomes provided 
from these programs in the pure outpatient setting. The general lack of studies regarding 
the efficacy of MTMs is likely due to confounding factors. A patient who has received an 
MTM service such as a CMR will more than likely have more providers and other 
interventions attempted at the same time given that having multiple chronic conditions is 
listed as a requisite to be a targeted beneficiary per Medicare. To provide a better 
understanding of the topic, specific references have been highlighted as core sources 
(Table 2). 
 
 
Table 2: Key Literature Cited 
 
Author(s) Document Date Background Relevance to Capstone 
Centers for 
Medicare 
and 
Medicaid 
Services 
Medication Therapy 
Management: 
https://www.cms.go
v/Medicare/Prescrip
tion-Drug-Coverage 
/PrescriptionDrugC
ovContra/MTM.html 
10 / 
2017 
Definition of MTM program including 
professional guides and memos for 
hospitals, providers, and patients. Contains 
what the US government requires of third-
party payers in order to obtain 
reimbursement and the benefits they 
receive in doing so. 
Kripalani, 
Jackson, 
Schipper, 
Coleman 
Promoting effective 
transitions of care 
at hospital 
discharge: a review 
of key issues for 
hospitalists 
09 / 
2007 
Looks into the effects of transitioning 
patients from hospital to outpatient care; the 
consequences and strategies to improve the 
process. Denotes medication reconciliation 
as an effective method to improve patient 
care during TOC. 
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UNM 
Medical 
Group, INC. 
Medication Therapy 
Management 
07 / 
2014 
Different states have different regulations on 
the definition of a “medical provider”. This 
protocol contains the method for billing for 
an institution in New Mexico, a state which 
has such modified definitions for 
pharmacists, via a variety of inpatient 
settings via CPT codes which are applied to 
Medicare Part D. 
Vermeire, 
Hearnshaw, 
Royen, 
Denekens 
Patient adherence 
to treatment: three 
decades of 
research. A 
comprehensive 
review. 
10 / 
2001 
Literature review on terminology 
differentiating compliance, concordance, 
and adherence; discusses the results of 
poor adherence on patient health in general. 
Does not contain any studies or statistical 
analysis but references and summarizes the 
effects of multiple studies and provides 
background as to potential role for MTM. 
Viswanathan 
et. al. 
Medication therapy 
management 
interventions in 
outpatient settings: 
a systematic review 
and meta-analysis 
01 / 
2015 
Meta-analysis determining effect of 
outpatient MTM on various health outcomes 
vs standard of care. Study observed 
statistically significant improvement in 
medication appropriateness and adherence 
in terms of doses taken. However, evidence 
was insufficient to determine significant 
effect on health outcomes. Provides 
evaluation on methods to improve future 
analysis, explanation of difficulty in isolating 
benefits, as well as methods to improve 
MTM process. 
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Research Design  
The purpose of this study is to evaluate a proposed workflow for conducting CMRs and 
analyze the effects of the constructed survey tool on this workflow. However, given that 
the implementation of the survey tool is reliant on the institution rather than personal 
research, a survey tool was also utilized to capture pharmacist opinions towards MTMs 
in an attempt to provide usable data. Both surveys were constructed in REDCap 
(Research Electronic Data Capture) – a web-based application developed by Vanderbilt 
University specifically for capturing data used in research studies (REDCap, 2017). The 
survey consisted of three distinct portions. The first section focused on beliefs regarding 
barriers to conducting MTMs with a question asking participants to rank their top three 
perceived barriers. The second section was for pharmacists who have conducted MTMs 
to estimate the time needed for the process. Finally, the third section utilized a Likert 
Scale to evaluate various statements regarding the effect of MTM’s on pharmacists and 
patients. The breakdown of the survey is attached (Appendix A). In terms of analysis, 
these results were used to gauge the need for a new workflow for MTMs. 
 
The workflow tool will serve as a hassle-free and efficient manner for gathering 
responses. Participants do not need any log-in credentials given that the tool uses a 
universal web address. Additionally, the tool contains a wide range of programmed 
question formats such that it is relatively easy for an administrator to use in case the need 
for further tool development arises. The survey tool was designed in order to shift a portion 
of the workload from pharmacists to pharmacy technicians and overcome the barrier of 
additional technological burden for the pharmacists. In doing so, it is hoped that 
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pharmacists will engage in more CMRs due to the lessened time burden. This proposed 
workflow would however increase the overall workload of pharmacy technicians. This 
program is in plans to be piloted with patients treated by physicians in the cardiovascular 
clinic at UK Healthcare who were designated by OutcomesMTM (the third-party web 
application connecting insurance companies and UK Healthcare) as needing a CMR. 
 
Previous Workflow 
The term “previous workflow” is utilized to describe the workflow that is to be replaced by 
the proposed tool. A graphic has been included to help delineate between the previous 
and proposed workflows [Figure 3, Panel A]. Hospital-admitted patients are targeted for 
CMR when their discharge orders have been placed. On a twice-weekly basis, a 
pharmacist merges the CMR eligible list provided from OutcomesMTM with the current 
inpatient list – this allows the pharmacist to determine which CMR eligible patients are 
currently in the hospital. They then consolidate the patient’s admitting medication history 
and any changes to their medication regimen that have been made during their stay. The 
pharmacist then fills out the form on the OutcomesMTM web-application with this 
information, creates a printable version and conducts the CMR with the patient by their 
bedside – they would correct any errors, fill out any missing information, as well as convey 
any medication-related problems that are present along with their recommended 
interventions for the patient. Afterwards the pharmacist completes the OutcomesMTM 
form using the information they had obtained from the interview and sends the patient (or 
designated recipient) their action plan packet.
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Figure 3: Previous and Proposed Workflows 
A. 
 
B.
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Piloted Workflow 
The piloted workflow differs from the one above with the inclusion of the REDCap survey tool and 
utilization of a pharmacy technician [see Figure 3, Panel B]. In this figure, the administrative 
pharmacist may at times act as the MTM pharmacist as well. After consolidating the patient’s 
medication history, the technician would email both the printable OutcomesMTM form and the 
REDCap survey link to the responsible pharmacist. After the pharmacist conducted the CMR, 
they would utilize the REDCap survey tool to provide the relevant information and notify the 
designated technician of its completion. Using the results from the REDCap survey, the technician 
would complete and submit the OutcomesMTM form, then send the patient (or designated 
recipient) their action plan packet. 
 
Data Collected 
Following implementation of the piloted workflow, the time required for completion of MTM’s was 
compared against the predicted times from the opinion survey as well as the recorded time from 
the sample pharmacist for Previous Workflow processes. Data analysis will focus mainly on the 
data obtained from the pharmacist opinion survey with time data used to determine if the Piloted 
Workflow is in fact an overall benefit to the process. 
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Results  
The survey was sent out via a listserv for UK Healthcare “Ambulatory Pharmacists” with two 
weeks allotted for response time. Of the potential 36 pharmacists eligible to answer, there were 
19 responses collected for a response rate of 52.8%. The survey results are listed below by 
survey section. 
Section 1: Barrier Identification 
 An initial question asked the respondent if they believed there were any barriers to conducting 
MTMs. If yes, the survey asked the pharmacists to rank the top three barriers in the list in order 
of significance. These barriers have been classified relative to the problem to which they relate. 
The following table provides the number of times each barrier was ranked. All 19 pharmacists 
provided responses for this section. The total score was calculated via a linear weight; each rank 
#1 counted as 3 points, #2 as 2 points, and #3 as 1 point. 
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Table 3: Barrier Perception Ranking (n=19) 
Barriers Related 
Problem 
Times 
ranked 
#1 
Times 
ranked 
#2 
Times 
ranked 
#3 
Total 
Score 
Difficulty Integrating MTMs into Normal 
Pharmacy Workflow 
Time 4 5 1 23 
Time Required of Pharmacy Personnel to 
Conduct MTM 
Time 3 3 3 18 
Difficulty in Engaging Patients Communication 3 2 2 15 
Difficulty in Contacting Patients due to Social 
Issues 
Communication 4 0 2 14 
Insufficient Patient Interest Value 1 2 3 10 
Time Required of Patient to Conduct MTM Time 2 1 1 9 
Lack of Private Counseling Area Resource 1 1 1 6 
Difficulty in Identifying Eligible Patients Resource 0 2 0 4 
Lack of Interface of Pharmacy System (i.e. 
Scriptpro) with Outcomes 
Resource 1 0 1 4 
Insufficient Patient Financial Benefit Value 0 0 3 3 
Complex Web-Submission Interface (i.e. 
Outcomes MTM) 
Resource 0 1 0 2 
Lack of Pharmacy Resources and Support Resource 0 1 0 2 
Unfamiliarity with MTM process Resource 0 1 0 2 
(Other) “Financial gain from completing an MTM 
- hard to understand the utility with such nominal 
payment; time to conduct an MTM does not 
justify the 'payment'” 
Time/Value 0 0 1 1 
Parking and Transportation Issues for Patients 
with Appointments 
Resource 0 0 1 1 
Insufficient Patient Health Benefit Value 0 0 0 0 
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Table 4: Barrier Perception Ranking: Respondents and Total Score (n=19) 
Pharmacist Score for 
Communication 
Score for 
Resource 
Score for Time Score for Value Highest 
Problem 
1 0 1 3 2 Time 
2 0 0 5 1 Time 
3 0 0 5 1 Time 
4 1 2 3 0 Time 
5 1 2 3 0 Time 
6 3 0 3 0 Communication 
/ Time 
7 0 5 1 0 Resource 
8 0 1 5 0 Time 
9 1 0 5 0 Time 
10 0 2 4 0 Time 
11 3 2 0 1 Communication 
12 0 5 1 0 Resource 
13 0 0 5.5* 0.5* Time 
14 3 0 0 3 Communication 
/ Value 
15 5 1 0 0 Communication 
16 3 0 2 1 Communication 
17 3 0 2 1 Communication 
18 3 0 1 2 Communication 
19 3 0 2 1 Communication 
Total 29 21 50.5 13.5 Time 
*Respondent provided a response in “Other” that is classified as both time and value based. 
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Section 2: Timing 
This section of the survey requested respondents who had previously conducted an MTM to 
estimate the time needed for each step in the process. Of the 19 respondents, one provided no 
response, one answered no, and one answered yes but did not provide any times. 
Table 5: Average Estimated Time for MTM Process (n=16) 
Step in Process Average 
Time 
(minutes) 
Standard 
Deviation    
(± minutes) 
Minimum 
Estimate 
(minutes) 
Maximum 
Estimate 
(minutes) 
Attain Patient Engagement 16.25 9.4 5 30 
Pre-Interview Preparation 25.63 17.4 5 60 
Patient Interview 30 14.61 10 60 
Documentation and 
Submission 
20 10.17 10 45 
Total Process 91.875 30.28 30 180 
 
Section 3: Barrier Statements 
The third and final section of the survey contained a variety of statements designed to reflect the 
barriers of Section 1. The questions were set-up via a 5-point Likert Scale with results as follows. 
Of the 19 survey respondents, the sixteen who completed Section 2, also completed this portion 
of the survey. Note: Reversed questions are denoted and have had both their question and 
responses in table reversed to reflect this such that all results of “Strongly Disagree” and 
“Disagree” reflect indication of the topic as a barrier. Total Score in this Section was calculated in 
a similar fashion to Table 3, with Strongly Disagree selections meriting a score of 5, Disagree 
equivalent to a score of 4, etc. 
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Table 6: Barrier Perception via Likert Scale Statements (n=16) 
Statement Related 
Problem 
Strongly 
Disagree 
Disagree Neither 
Agree 
nor 
Disagree 
Agree Strongly 
Agree 
Total 
Score 
[Reversed] Reimbursement for MTMs 
does match the work required. 
Time / 
Value 
5 8 3 0 0 66 
Patients understand the importance 
of MTMs. 
Communi-
cation / 
Value 
6 5 4 1 0 64 
[Reversed] With third party payers 
holding back reimbursement based 
on MTM performance, there is not 
strong financial incentive to complete 
MTMs. 
Value 5 7 1 3 0 62 
My colleagues have a positive 
disposition towards MTMs. 
Value 2 6 6 2 0 56 
[Reversed] There are not more 
efficient methods of providing patient 
care than MTMs. 
Time 2 5 8 1 0 56 
From a solely financial standpoint, 
MTMs are profitable. 
Value 2 2 7 5 0 49 
[Reversed] The process of 
documentation does not require too 
much time for MTMs to be beneficial.* 
Time / 
Value 
1 6 
 
4 4 0 49* 
Conducting MTMs is a beneficial use 
of my time. 
Time / 
Value 
1 1 5 6 3 39 
[Reversed] MTMs are a useful 
component of a pharmacist’s 
responsibilities. 
Value 1 1 3 10 1 39 
Because of the lack of provider 
status, MTMs provide a strong 
opportunity for pharmacists to directly 
affect patient care.* 
Value 0 2 4 8 1 37* 
APPE students and interns should be 
assigned to do more MTMs. 
Resource 1 0 4 7 4 35 
[Reversed] MTMs will be an important 
part of a pharmacist’s activities in the 
future. 
Value 1 0 4 7 4 35 
MTMs are a vital portion of patient care. Value 0 2 2 8 4 34 
More MTMs would be conducted if 
pharmacists only needed to conduct 
the patient interview and develop the 
action plan. 
Time 0 0 5 7 4 33 
I fully understand the process of 
conducting MTMs. 
Resource 0 1 0 8 7 27 
*One of the sixteen respondents chose not to provide a response to this statement. Total score for this statements is artificially 
lower as a result. 
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Table 7: Barrier Perception via Likert Scale Statement: Respondents and Average Score 
(n=16) 
Pharmacist Score for 
Communication  
(1 statement) 
Average Score for 
Resource  
(2 statements) 
Average Score for 
Time  
(5 statements) 
Average Score for 
Value  
(11 statements) 
1 5 3 4 3.55 
2 4 2 3.2 3.09 
3 5 2 4.6 4.55 
4 4 2 3.2 2.45 
5 4 2 3.4 3.09 
6 4 2.5 2.6 2.8* 
7 5 1 3.2 3.27 
8 3 1.5 2.6 2.64 
9 3 1.5 2.8 2.91 
10 3 2 2.6 2.73 
11** - - - - 
12 2 2.5 2.6 2.73 
13** - - - - 
14 5 2.5 3.6 3.45 
15 3 1.5 2.25* 2.4* 
16 5 2 3.4 3.45 
17 5 1 2.4 3.09 
18 4 2 2.6 2.45 
19*** - - - - 
Total 
Average 
4 1.94 3.07 3.04 
*Average calculated with one less field due to non-response. 
**Pharmacists who did not provide response; number designation kept for consistency. 
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Discussion  
  
   Overall this survey was helpful in elucidating the barriers towards conducting CMRs at the 
University of Kentucky. Utilizing the total score, the top barriers that emerged were based on time 
and communication rather than value or resource. 
1. Difficulty Integrating MTMs into Normal Pharmacy Workflow (Time; 23) 
2. Time Required of Pharmacy Personnel to Conduct MTM (Time; 18) 
3. Difficulty in Engaging Patients (Communication; 15) 
4. Difficulty in Contacting Patients due to Social Issues (Communication; 14) 
5. Insufficient Patient Interest (Value; 10) 
6. Time Required of Patient to Conduct MTM (Time; 9) 
 
It is important to note that there were more categories for the barriers of resource and value but 
that the sum of the categories would still not displace time and communication as the top barriers 
in this regard [see Table 4]. The difference between the top two barriers reflects a small potential 
distinction in the fix needed in the MTM process. Difficulty in integrating MTMs into the normal 
workflow indicates that the pharmacists believe an efficient process can exist that will allow them 
to conduct MTMs with their current workload. That being said, even without this distinction, the 
pharmacists heavily rank issues with the MTM’s process over needing additional resources to 
incorporate MTMs normally. Barriers number 3 and 4 indicate that pharmacists are not as 
concerned over the applicability or use of MTMs. 
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Utilizing the total score measure with Section 3 representing statements of barriers, a similar 
trend emerges. Based on the average total score of 48, any scores below this represent an overall 
agreement with the statement and lowered significance of the barrier. The most contested 
statements are as follows: 
1. Reimbursement for MTMs does match the work required. (Time/Value; 66) 
2. Patients understand the importance of MTMs. (Communication/Value; 64) 
3. With third party payers holding back reimbursement based on MTM performance, there is 
not strong financial incentive to complete MTMs. (Value; 62) 
4. There are not more efficient methods of providing patient care than MTMs. (Time; 56) 
5. My colleagues have a positive disposition towards MTMs. (Time; 56) 
 
These statements do not directly scale with the rankings of the survey’s first section as these 
statements add the consideration of problems with pharmacy reimbursement and third-party 
involvement in MTMs. The respondents maintain their desire for better patient outreach and 
understanding of the benefits (shown by number 2) as well as their belief that the process is 
beneficial (shown by number 4 and 5). Given that the statements were not equally weighted for 
the representative problems, the average Likert Scale rating must be used for comparison 
between the barriers. 
- Communication; 1 Statement = 4 
- Time; 5 Statements = 3.07 
- Value; 11 Statements = 3.04 
- Resource; 2 Statements = 1.94 
The averages show that time and value considerations remain more important than those for the 
amount of pharmacy given resources at hand. Together, both sections seem to indicate that the 
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problems for MTM that a pharmacy department can internally address in order to have more 
widespread utilization are the time needed to conduct a CMR along with communication with the 
patients. I believe that the proposed workflow strikes at the heart of this issue and will prove useful 
for these concerns. The tool developed correctly pinpoints time as a factor, and although 
communication needs to be worked on as well, the new workflow is an internal process that can 
be implemented without patient input. 
 The answers that the pharmacists provided for the first and third sections of the survey did 
not show any statistically significant correlation with their estimation of MTM process time in the 
second section. Linear regression utilization total estimated time separately against rank score 
from the first section and average score from the third section did not show any significant p-
values, nor high R-square values. 
 
Figure 4: Linear Regression: Total Time vs. Rank Score 
Regression Statistics    
Multiple R 0.276954    
R Square 0.076704    
Adjusted R Square -0.23745    
Standard Error 42.19848    
Observations 16    
     
  Coefficients 
Standard 
Error t Stat P-value 
Intercept 38.51176 68.18928 0.564777 0.582629 
Rank Score Communication 11.43104 15.12577 0.755733 0.464386 
Rank Score Resource 11.78628 12.08226 0.975503 0.348566 
Rank Score Time 8.533923 12.99282 0.656818 0.523695 
Rank Score Value 0 0 65535 #NUM! 
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Figure 5: Linear Regression: Total Time vs. Statement Average Score 
Regression Statistics    
Multiple R 0.39972128    
R Square 0.159777102    
Adjusted R Square -0.145758498    
Standard Error 42.04533127    
Observations 16    
     
  Coefficients 
Standard 
Error t Stat P-value 
Intercept 87.1414252 71.8864 1.21221 0.250826 
Statement Communication Average 
Value -14.81162735 15.65929 -0.94587 0.36453 
Statement Resource Average Value 5.057105822 24.29886 0.208121 0.838938 
Statement Time Average Value -33.83117581 41.13095 -0.82252 0.428249 
Statement Value Average Value 51.9238278 44.30084 1.172073 0.265927 
     
     
     
With regards to the estimations of time for the process, the average estimation for a complete 
CMR was around 92 minutes, with only 30 minutes designated as time spent during a patient 
interview. If the pharmacist is considered needed for the patient interview and half of the time 
spent in pre-interview preparation (e.g. reviewing the patient profile), then the average time split 
between technician and pharmacist would be about 50 minutes to 42 minutes respectively. At an 
average salary of $13 per hour for a pharmacy technician and $50 per hour for a pharmacist, the 
cost of an MTM via previous workflow of ~$77 drops to ~$46 per patient. 
Figure 6: Cost per Average MTM Conducted 
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Conclusion  
  
  This study collected survey data regarding pharmacist opinions on barriers towards 
conducting CMRs and has shown two major problem areas to focus on. Pharmacists appear to 
have a good understanding of the benefits of CMRs and would be willing to incorporate it into 
their workflow for the benefit of the patient. The developed tool that is awaiting implementation 
should prove to be useful in alleviating the issue of time allotment. However, although the tool will 
reduce the time spent by pharmacists on each CMR, there is no guarantee that this saved time 
will be “reinvested” into CMRs or if it will be used to address the many other demands. 
Additionally, the noted concerns with patient communication will likely require patient input to 
improve as they involve transferring the pharmacist’s understanding of value of the CMR to the 
patient. 
 Future directions with this research involve the collection of timing data for pharmacists 
conducting CMRs with both the “previous workflow” and the proposed workflow to compare 
against the estimated time data collected here. Comparison against each other would provide 
further clarification on financial savings by shifting of work from pharmacist to pharmacy 
technician. Additionally, research into methods of addressing the communication problem with 
patients would serve as a helpful addition to the efforts on the pharmacists’ side.   
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Limitations   
This study’s limitations center on the number of polled pharmacists. Although the 
sample size for this study was low, the survey respondents were highly representative of 
the target for the developed process. This survey does not poll the pharmacists who are 
considered for implementation in the new process, nor does it address the thoughts of 
pharmacy technicians or patients regarding the barriers to CMRs. Additionally, there are 
the traditional concerns with survey-based studies regarding the time needed for the 
voluntary survey and the resulting response amounts. This study also had a lack of 
directly timed data for the “previous workflow” given that only one pharmacist is currently 
conducting these MTMs. 
In terms of analysis, the linear modeled total score used to determine barrier 
significance could be argued as not completely representative of pharmacist opinions 
given the relative nature of ranking. The method used of analysis is not a replacement for 
statistical analysis but provides the needed picture regarding whether or not to proceed 
with process implementation. 
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Appendix A: Survey 
 
--- Page 1 --- (Consent Script)  
  
  Hello! My name is Allan Tao, I am a PY4 student at UK and am conducting this survey to better 
understand pharmacy personnel opinions related towards the process of Medication Therapy Management 
(MTM). I am asking for your participation in this survey to aid me with my MPA capstone research 
project. If you voluntarily participate in this study you will be one of approximately 36 pharmacists at 
University of Kentucky HealthCare asked to do so.  
  
You have been asked to participate in this survey because you are a pharmacist who may 
potentially be tasked with conducting MTMs in the Transitions-of-Care setting. This survey will take 
approximately 10 minutes to complete and will ask about your opinions related to the workflow process 
and significance of MTMs. Please note, the phrase “Medication Therapy Management” will be 
considered synonymous with “Comprehensive Medication Review” for the purposes of this survey. The 
information generated from this research will be used to inform ongoing local, regional and national 
discussions about the value of MTMs.  
  
To ensure all responses to the first survey on pharmacists’ opinions are anonymous, a universal 
URL link has been provided to all participants. Results from REDCap will not denote any information as 
to respondents’ identity. Additionally, there are no queries as to your identity in the survey.  
  
There are no known risks associated with completing this survey. Taking part in this survey 
research is completely voluntary. Your employment status will not be affected in any way, regardless of 
whether you participate or not. I am not employed by University of Kentucky HealthCare. If you choose 
not to participate, there will be no penalty or loss of benefits to you. If you do choose to participate, you 
are free to skip any survey question that you do not want to answer and you can discontinue the survey at 
any time. Although you will not personally benefit by completing the survey, the information that you 
provide may help inform ongoing discussions related to the significance of  
MTMs.  
  
This study has been reviewed by the University of Kentucky Medical Institutional Review Board. 
If you have questions about this study, you may call myself at 859-559-5885 or my MPA capstone 
advisor, Karen Blumenschein at 859-257-5778. If you have any questions about your rights as a volunteer 
in this research, you may contact the staff in the Office of Research Integrity at the University of 
Kentucky at 859-257-9428 or toll free at 1-866-400-9428.  
  
Thank you for your time and we appreciate your consideration in completing this survey.  
  
Sincerely,  
  
 
Allan Tao and Karen Blumenschein  
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I understand the intent, potential risks, and anonymity of this survey and am willing to complete it.  
- Yes  
- No  
{If no, will close survey}  
  
 
--- Page 2 ---  
  
Do you believe there are barriers to conducting MTMs?  
- Yes  
- No  
{If no, skip to page 4}  
  
  
--- Page 3 ---  
  
Which of the following do you believe are barriers to conducting MTMs? (Select the top three barriers in 
order of significance)  
- Complex Web-Submission Interface (i.e. OutcomesMTM)  
- Difficulty in Contacting Patients due to Social Issues  
- Difficulty in Engaging Patients  
- Difficulty in Identifying Eligible Patients  
- Difficulty Integrating MTMs into Normal Pharmacy Workflow  
- Insufficient Patient Financial Benefit  
- Insufficient Patient Health Benefit  
- Insufficient Patient Interest  
- Lack of Interface of Pharmacy System (i.e. Scriptpro) with Outcomes  
- Lack of Pharmacy Resources and Support  
- Lack of Private Counseling Area  
- Parking and Transportation Issues for Patients with Appointments  
- Time Required of Patient to Conduct MTM  
- Time Required of Pharmacy Personnel to Conduct MTM  
- Unfamiliarity with MTM process  
- Other:  
o Free Text Box  
  
--- Page 4 ---  
  
Have you conducted an MTM in the past?  
- Yes  
- No  
{If no, skip to page 3}  
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When attempting to recruit an eligible patient for an MTM, how much time (in minutes) is needed to 
attain patient engagement? Consider time required to initiate patient contact, to provide relevant 
information, and to schedule an interview.  
  
When conducting an MTM, how much time (in minutes) is needed for pre-interview preparation? 
Consider time required to consolidate medication history and review patient profile.  
  
When conducting an MTM, how much time (in minutes) is needed for the patient interview portion? 
Consider time required to conduct full interview as well as develop and communicate action plan.  
  
When conducting an MTM, how much time (in minutes) is needed for documentation and submission 
process to a web-interface (i.e. OutcomesMTM). Consider time required to fill out web-form and send 
take-home packet to appropriate recipient.  
  
--- Page 5 ---  
  
Please indicate your level of agreement/disagreement with the following statements using the scale 
shown below:  
1  2  3  4  5  
Strongly Disagree Disagree  Neither Agree nor 
Disagree  
Agree  Strongly Agree  
  
(each as an individual question)  
- I fully understand the process of conducting MTMs.  
- MTMs are a vital portion of patient care.  
- Conducting MTMs is a beneficial use of my time.  
- More MTMs would be conducted if pharmacists only needed to conduct the patient interview and 
develop the action plan.  
- From a solely financial standpoint, MTMs are profitable.  
- There are more efficient methods of providing patient care than MTMs.  
- MTMs are not a useful component of a pharmacist’s responsibilities.  
- My colleagues have a positive disposition towards MTMs.  
- Reimbursement for MTMs does not match the work required.  
- Patients understand the importance of MTMs.  
- The process of documentation requires too much time for MTMs to be beneficial.  
- Because of the lack of provider status, MTMs provide a strong opportunity for pharmacists to 
directly affect patient care.  
- MTMs will not be an important part of a pharmacist’s activities in the future.  
- APPE students and interns should be assigned to do more MTMs.  
- With third party payers holding back reimbursement based on MTM performance, there is strong 
financial incentive to complete MTMs.   
